Details of Drug-Drug Interaction
| Drug General Information (ID: DDITXN3G69) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Alfuzosin | Drug Info | Terazosin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antihypertensive Agents | Antineoplastics | |||||||
| Structure | |||||||||
| Mechanism of Alfuzosin-Terazosin Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive hypotensive effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Alfuzosin | Terazosin | |||||||
| Mechanism |
Hypotensive effects Alpha-1 adrenergic receptor Antagonist |
Hypotensive effects Alpha-1 adrenergic receptor Antagonist |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Adrenergic receptor alpha-1 | Structure Sequence | |||||||
| Protein Family | G-protein coupled receptor 1 family | ||||||||
| Protein Function |
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | The use of alfuzosin in combination with other alpha-blockers should be avoided. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Uroxatral (alfuzosin). sanofi-aventis , Bridgewater, NJ. | ||||||||||||||||||